Expert Review of Clinical Immunology最新文献_第2页

Atacicept in IgA nephropathy. 阿他塞普在IgA肾病中的作用。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-09-01 Epub Date: 2026-09-11 DOI: 10.1080/1744666X.2026.2731960

Sheila A Doggrell

引用次数: 0

The actionable exposome. 可起诉的暴露者。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-09-01 Epub Date: 2026-09-28 DOI: 10.1080/1744666X.2026.2738409

Krisna C Bhargava, Uta S Guo, Otman Maoued, Henriett Diana Szucs, Leonardo Trasande, Jonathan H Freedman

引用次数: 0

Exploring novel and evolved tools in atopic dermatitis diagnosis. 探索特应性皮炎诊断的新工具。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-09-01 Epub Date: 2026-09-15 DOI: 10.1080/1744666X.2026.2734034

Domenico Caranci, Francesco Briguori, Maddalena Spalliero, Maddalena Napolitano

{"title":"Exploring novel and evolved tools in atopic dermatitis diagnosis.","authors":"Domenico Caranci, Francesco Briguori, Maddalena Spalliero, Maddalena Napolitano","doi":"10.1080/1744666X.2026.2734034","DOIUrl":"10.1080/1744666X.2026.2734034","url":null,"abstract":"Introduction: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease and is clinically and biologically heterogeneous. Its diagnosis remains clinical, supported by validated criteria, with no single confirmatory test, yet the expansion of targeted systemic therapies has intensified the need for objective tools to support diagnosis and stratify patients.Areas covered: This review summarizes the established clinical framework of AD diagnosis and the emerging tools intended to complement it: circulating and skin-derived biomarkers, minimally invasive tape stripping, the skin microbiome, instrumental barrier assessment, noninvasive biofluids, advanced optical imaging (reflectance confocal microscopy, optical coherence tomography and line-field confocal OCT) and artificial-intelligence and digital tools, with attention to special populations. The discussion is informed by a multi-database search (PubMed, Embase, Cochrane Library and Web of Science) to 2026.Expert opinion: Clinical diagnosis remains the reference standard, and the experienced clinician still outperforms any single test. The tools reviewed are promising adjuncts for differential diagnosis, endotyping, response prediction and monitoring, but few are standardized or prospectively validated; priorities for validation and equitable clinical integration are outlined.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"989-1001"},"PeriodicalIF":4.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Switchback from biosimilar tumor necrosis factor-alpha inhibitors to reference medicines: a review. 从肿瘤坏死因子- α抑制剂生物仿制药转向参考药物：综述

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-09-01 Epub Date: 2026-09-24 DOI: 10.1080/1744666X.2026.2727537

Robert Moots, Sascha Gerdes, Giampiero Girolomoni, Jonas Halfvarson, Charlotte Both, Ines Brückmann, Silvio Danese

{"title":"Switchback from biosimilar tumor necrosis factor-alpha inhibitors to reference medicines: a review.","authors":"Robert Moots, Sascha Gerdes, Giampiero Girolomoni, Jonas Halfvarson, Charlotte Both, Ines Brückmann, Silvio Danese","doi":"10.1080/1744666X.2026.2727537","DOIUrl":"10.1080/1744666X.2026.2727537","url":null,"abstract":"Introduction: Switching from reference biologics to biosimilars usually occurs for non-medical reasons, such as cost-driven formulary changes. However, despite biosimilars having the same efficacy and similar safety profiles as their reference products, some patients discontinue treatment and 'switchback' to the reference product.Areas covered: In this narrative review, the authors examine the frequency and causes of switchback reported in journal articles and congress abstracts published between 2016 and 2023, evaluating patients who switched from biosimilars back to the reference biologic. As almost all publications focused on tumor necrosis factor inhibitors, and so the authors restricted their analysis to this drug class.Expert opinion: Evidence suggests that switchback rates are low, with most studies of at least 100 patients reporting rates of less than 20%. The main reasons for switchback are typically patient-reported loss of effectiveness (usually judged subjectively) and side effects. These findings support the view that the nocebo ('negative placebo') effect is a plausible and likely contributor to switchback. Healthcare professional and patient education on the effectiveness and safety of biosimilars is needed and will be vital to counter misinformation and minimize the nocebo effect, allowing biosimilars to continue contributing to sustainability in healthcare.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"975-988"},"PeriodicalIF":4.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148886751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oxidative stress: a pivotal regulator of inflammation and endotypes in chronic rhinosinusitis. 氧化应激：慢性鼻窦炎炎症和内源性的关键调节因子。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-09-01 Epub Date: 2026-10-01 DOI: 10.1080/1744666X.2026.2738383

Xinlei Niu, Xiaozhe Yang, Haiyan Xu, Fei Gao, Xiaoyu Pu, Zhongyi Wang, Chao Cai, Xiangdong Wang, Luo Zhang

{"title":"Oxidative stress: a pivotal regulator of inflammation and endotypes in chronic rhinosinusitis.","authors":"Xinlei Niu, Xiaozhe Yang, Haiyan Xu, Fei Gao, Xiaoyu Pu, Zhongyi Wang, Chao Cai, Xiangdong Wang, Luo Zhang","doi":"10.1080/1744666X.2026.2738383","DOIUrl":"10.1080/1744666X.2026.2738383","url":null,"abstract":"Introduction: Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disease with distinct immune endotypes and variable clinical outcomes. Oxidative stress contributes to this heterogeneity by linking epithelial injury, persistent inflammation, and tissue remodeling.Areas covered: PubMed was searched for relevant studies published between January 2016 and December 2025. Earlier seminal studies were included when appropriate. Excess reactive oxygen species (ROS) and impaired antioxidant defenses disrupt mucosal redox balance and sustain inflammation. Eosinophils and neutrophils contribute through distinct but overlapping oxidative mechanisms. Their coexistence may intensify inflammation in mixed endotypes. Redox alterations may aid endotype classification, prognosis, and treatment assessment. Antioxidants and other redox-targeted approaches have shown promise in experimental models.Expert opinion: Clinical evidence for redox-targeted treatment remains limited. Defining endotype-specific redox profiles may improve disease stratification and clarify whether restoring redox balance improves clinical outcomes.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1039-1049"},"PeriodicalIF":4.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149074184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Follicular lymphoma and the microenvironment: potential targets and biomarkers. 滤泡性淋巴瘤和微环境：潜在靶点和生物标志物。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-09-01 Epub Date: 2026-09-10 DOI: 10.1080/1744666X.2026.2731956

Zhi-Zhang Yang, Stephen M Ansell

{"title":"Follicular lymphoma and the microenvironment: potential targets and biomarkers.","authors":"Zhi-Zhang Yang, Stephen M Ansell","doi":"10.1080/1744666X.2026.2731956","DOIUrl":"10.1080/1744666X.2026.2731956","url":null,"abstract":"Instruction: Follicular lymphoma (FL) is an indolent B cell malignancy characterized by recurrent genetic alterations, yet its clinical course is highly variable and not fully explained by tumor-intrinsic features alone. Increasing evidence highlights the tumor microenvironment (TME) as a critical regulator of disease progression, therapeutic response, and immune escape.Areas covered: FL TME is composed of diverse cellular elements, including T cell subsets, tumor-associated macrophages, stromal cells, and follicular dendritic cells, which collectively provide survival signals and shape immune dysfunction. These interactions have led to the identification of potential therapeutic targets, such as immune checkpoint molecules, macrophage polarization pathways, and stromal-tumor signaling axes. In parallel, microenvironment-derived biomarkers, including specific immune cell compositions, spatial organization patterns, and gene expression signatures, are emerging as important predictors of prognosis and treatment outcomes. Advances in single-cell and spatial profiling technologies have further refined our understanding of TME heterogeneity, enabling the discovery of clinically relevant targets and biomarkers.Expert opinion: Together, these insights support a more integrated model of FL biology and provide a foundation for developing microenvironment-directed therapies and precision medicine approaches.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1003-1017"},"PeriodicalIF":4.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SARS-CoV-2 management strategies in B-Cell-depleted people with multiple sclerosis: from prevention to antiviral treatment. b细胞耗竭的多发性硬化症患者的SARS-CoV-2管理策略：从预防到抗病毒治疗

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-09-01 Epub Date: 2026-09-15 DOI: 10.1080/1744666X.2026.2731966

Julia Feige, Larissa Hauer, Johann Sellner

{"title":"SARS-CoV-2 management strategies in B-Cell-depleted people with multiple sclerosis: from prevention to antiviral treatment.","authors":"Julia Feige, Larissa Hauer, Johann Sellner","doi":"10.1080/1744666X.2026.2731966","DOIUrl":"10.1080/1744666X.2026.2731966","url":null,"abstract":"Introduction: Multiple sclerosis (MS) is a leading cause of neurological disability in young adults, necessitating early high-efficacy disease-modifying therapies (DMTs). Monoclonal antibodies targeting the CD20 antigen are a cornerstone of effective disease control, but depletion of peripheral B-cells blunts the humoral immune response. This review synthesizes current evidence on COVID-19 risk, prevention and treatment in anti-CD20-treated people with multiple sclerosis (pwMS).Areas covered: A PubMed literature search through June 2026 identified relevant studies on anti-CD20 therapies and COVID-19 in pwMS. While MS itself does not increase COVID-19 susceptibility, anti-CD20-induced immunosuppression predisposes patients to severe COVID-19 outcomes and protracted or relapsing infections. Furthermore, B-cell depletion severely impairs vaccine efficacy, leaving patients with markedly diminished or absent neutralizing antibody responses.Expert opinion: To mitigate COVID-19 risks, future strategies should focus on three pillars. First, strategic switching among anti-CD20 antibodies to improve vaccine efficacy. Second, variant-targeted monoclonal antibodies for pre- and post-exposure prophylaxis in patients lacking robust humoral responses. Finally, early administration of direct-acting small-molecule antivirals to halt viral replication before hyperinflammation. Moving forward, integrating real-world data, identifying immunogenetic risk biomarkers, and evaluating long-term combinations of vaccine-passive immunizations will help safely sustain high-efficacy MS treatments.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1019-1037"},"PeriodicalIF":4.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148967344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complicated and refractory celiac disease: a model of antigen-independent immune escape and lymphoproliferation. 复杂难治性乳糜泻：抗原非依赖性免疫逃逸和淋巴细胞增殖的模型。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-08-01 Epub Date: 2026-08-28 DOI: 10.1080/1744666X.2026.2724857

Sara Massironi, Maria Galbiati, Flavia Scatena, Paoletta Preatoni, Luca Albarello, Ilaria Lodola, Maurilio Ponzoni, Silvio Danese

{"title":"Complicated and refractory celiac disease: a model of antigen-independent immune escape and lymphoproliferation.","authors":"Sara Massironi, Maria Galbiati, Flavia Scatena, Paoletta Preatoni, Luca Albarello, Ilaria Lodola, Maurilio Ponzoni, Silvio Danese","doi":"10.1080/1744666X.2026.2724857","DOIUrl":"10.1080/1744666X.2026.2724857","url":null,"abstract":"Introduction: Celiac disease (CeD) is an immune-mediated enteropathy triggered by dietary gluten and treated with a gluten-free diet. However, a subset of patients develops refractory or complicated forms characterized by persistent immune activation and increased risk of malignant transformation. These conditions challenge the traditional view of CeD as a fully reversible, antigen-driven disorder.Areas covered: This narrative review reframes refractory and complicated CeD as a biological continuum driven by sustained immune dysregulation and partial independence from the antigenic trigger. Literature was identified through PubMed and Embase searches (January 2000-March 2026), focusing on clinical, translational, and molecular studies relevant to refractory and complicated CeD. Current definitions and the clinical spectrum are discussed, spanning refractory CeD types 1 and 2 (RCeD1 and RCeD2), ulcerative jejunoileitis, intestinal lymphomas, and small bowel adenocarcinoma. Immunological mechanisms, including aberrant intraepithelial lymphocyte populations, clonal T-cell expansions, and cytokine-driven survival pathways, especially IL-15 signaling, are discussed. Evidence linking chronic inflammation, immune escape, and lymphoproliferation is reviewed.Expert opinion: Current diagnostic and therapeutic strategies remain inadequate to identify early immune escape and pre-malignant evolution. A shift toward biologically driven risk stratification and integration of molecular diagnostics is essential to enable early identification and targeted intervention in high-risk patients.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"901-913"},"PeriodicalIF":4.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148826500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lamotrigine and other therapy-associated HLH syndromes: a review. 拉莫三嗪和其他治疗相关的HLH综合征：综述

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-08-01 Epub Date: 2026-08-16 DOI: 10.1080/1744666X.2026.2718332

Yaswanta K Gummadi, Ashley Sutherland, Steven Rowe, Luke Y C Chen

{"title":"Lamotrigine and other therapy-associated HLH syndromes: a review.","authors":"Yaswanta K Gummadi, Ashley Sutherland, Steven Rowe, Luke Y C Chen","doi":"10.1080/1744666X.2026.2718332","DOIUrl":"10.1080/1744666X.2026.2718332","url":null,"abstract":"Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of pathologic immune activation that can occur secondary to medical interventions including immunomodulatory therapies such as immune checkpoint inhibitors and stem cell transplantation. However, lamotrigine and other anti-seizure medications (ASMs), which are not thought of as overtly immunogenic, are an important emerging cause and exploring the pathophysiology of lamotrigine-associated HLH may improve our understanding of secondary HLH.Areas covered: We completed a literature search in EMBASE and MEDLINE for English language articles indexed between 1 January 1966, and 31 August 2025. We review the current understanding of the diagnosis and pathophysiology of known causes of immunomodulatory therapy-associated HLH including chimeric antigen receptor T-cell (CAR-T) therapy and immune checkpoint inhibitors. We then discuss the clinical overlap between ASM-induced HLH & drug-induced hypersensitivity syndrome (DIHS) and explore underlying immune pathophysiology including mechanisms and potential contributors including host genetic factors and viral etiologies.Expert commentary: Lamotrigine-induced HLH has significant clinical overlap with DIHS, with common features of fever, diffuse skin rash, and multi-organ failure. Further advances in immune profiling of patients with ASM-associated HLH will improve our understanding of the pathogenesis and promote the development of novel immunotherapy agents for the treatment of the condition.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"835-844"},"PeriodicalIF":4.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148705974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Castleman disease: application of modern classification in a Canadian center. Castleman病：现代分类在加拿大中心的应用。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-08-01 Epub Date: 2026-08-14 DOI: 10.1080/1744666X.2026.2716693

Rebecca MacLeod, Mark Trinder, Liliana Wolak, Stephanie Quon, Marley Blommers, Mariam Goubran, Julia Varghese, Erica Peterson, Luke Y C Chen

{"title":"Castleman disease: application of modern classification in a Canadian center.","authors":"Rebecca MacLeod, Mark Trinder, Liliana Wolak, Stephanie Quon, Marley Blommers, Mariam Goubran, Julia Varghese, Erica Peterson, Luke Y C Chen","doi":"10.1080/1744666X.2026.2716693","DOIUrl":"10.1080/1744666X.2026.2716693","url":null,"abstract":"Background: CD (Castleman disease) is a rare and heterogeneous condition that poses a diagnostic and management challenge. Classification of CD has changed dramatically in recent years. This study aims to describe our experience with diagnosis and treatment of CD at a center in Canada.Research design and methods: We conducted a retrospective study of our cohort of CD patients evaluated and treated at the University of British Columbia between 2016-2025.Results: A total of 23 patients with biopsy-confirmed CD were included. 7/23 had unicentric CD (UCD), 1/23 had Oligocentric CD (OligoCD), and 15/23 had multicentric CD (MCD). All MCD cases were idiopathic (iMCD) and of these, 3/15 had iMCD-TAFRO (thrombocytopenia, anasarca, fever, reticulin myelofibrosis or renal dysfunction, and organomegaly), 4/15 had iMCD-idiopathic plasmacytic lymphadenopathy (iMCD-IPL), and 8/15 had iMCD-not otherwise specified (iMCD-NOS). Median time to diagnosis was shortest for iMCD-TAFRO (1 month) and longest in iMCD-IPL (82 months). 100% of iMCD-TAFRO, 100% of iMCD-IPL, and 86% of iMCD-NOS cases treated with Siltuximab or Tocilizumab had at least a partial response.Conclusions: This study demonstrates the heterogeneous presentation, natural history, and response to treatment of CD in a North American center, and highlights the importance of awareness of the different subtypes of CD. Key limitations are its retrospective design and small sample size.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"941-948"},"PeriodicalIF":4.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148720646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0